Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in human and veterinary medicine for their analgesic and anti-inflammatory properties. 1 They inhibit cyclo-oxygenase-1 and -2 (COX-1 and -2), reducing production of prostaglandins and other inflammatory mediators. COX-1 is present in all tissues, while COX-2 levels are normally low but increase in response to tissue injury. 1 Common examples include aspirin, indomethacin, diclofenac and the 2-arylpropanoic acids (2-APAs; a.k.a. profens), including ibuprofen 1. 2-APA drugs contain a chiral centre and their S-enantiomers potently inhibit COX activity, while the R-enantiomers are much less active. 2, 3 These drugs are often given as racemic mixtures. Ibuprofen 1 4-7 fenoprofen 3, 3,8 flobufen, 9 flurbiprofen 4, 10 ketoprofen 5 2 and naproxen 6 11 undergo uni-directional conversion to the single S-enantiomer in vivo. R-Ibuprofen 1 is converted to R-ibuprofenoyl-CoA 2 12,13 and chirally inverted by an epimerase. 7, 14, 15 Finally, hydrolysis of the CoA ester gives S-ibuprofen 1. Other 2-APAs are assumed to be inverted by the same enzymes as for ibuprofen 1, but this has not been proven.
Cloning of 'ibuprofenoyl-CoA epimerase' showed that it was identical to a-methylacyl-CoA racemase (AMACR), which also catalyses chiral inversion of other 2-methyl-fatty acyl-CoA esters. 16 The reaction involves removal of the substrate a-proton followed by non-stereoselective reprotonation. 17 Protein levels and activity are increased in prostate, some colon and other cancers, 16 and AMACR has attracted interest as a novel marker 18 and drug target. 19, 20 Although the acyl groups of AMACR substrates are known to be structurally diverse, 16 no systematic study of substrate structure has been reported. This communication reports the first such systematic study and shows that all of the tested 2-APA-CoA esters are good substrates. High doses of ibuprofen reduce the risk of developing prostate cancer 26 and these results suggest that the interaction of 2-APA-CoA esters with AMACR may contribute to this chemopreventive effect.
Initially, a number of 2-APA-CoA esters were synthesized for evaluation. Ibuprofenoyl-CoA 2 was chosen, as a known substrate for native rat AMACR 14 and the homologous MCR from M. tuberculosis.
21 AE-Fenoprofenoyl-CoA 7, AE-flurbiprofenoyl-CoA 8, and S-ketoprofenoyl-CoA 9 were synthesized, as these 2-APAs undergo chiral inversion in vivo.
2,3,8,10 S-Naproxenoyl-CoA 10 was also synthesized, as it is structurally related but its chiral inversion in vivo is reported to be extremely limited. 11 The 2-APAs reacted with carbonyl diimidazole 20, 22 to form the acyl-imidazole intermediates, the presence of which was confirmed by 1 H NMR. These intermediates were immediately treated with CoA-SH, to afford the desired esters on B10 mg scales (ESI,w Scheme S1). S-2-Methyldecanoyl-CoA 11 was also synthesized as a known substrate of human recombinant AMACR 1A. 17, 23 These acyl-CoA esters were incubated at ca. 400 mM with human AMACR 1A in the presence of 2 H 2 O for 416 h and activity was monitored by exchange of the a-proton for 2 H by 1 H NMR. 17 Exchange of the a-proton for 2 H at ca. 70-90% conversion was observed for all 2-APA-CoAs. The signal for the methyl group on C-2 appears as an asymmetrical doublet (Fig. 1) , composed of the unresolved triplet of the 2 H-labelled product superimposed on the doublet of unreacted substrate. There was also a reduction in the intensity of the signal for 2-H. The known substrate, S-2-methyldecanoyl-CoA 11, was converted 495% under the same conditions. 17 No exchange was observed in negative controls containing heat-inactivated enzyme.
Experiments were then performed to determine whether chiral inversion of the 2-APA-CoA had also occurred in addition to a-proton exchange. Thus, ca. 10 mg of S-ketoprofenoyl-CoA 9 and S-naproxenoyl-CoA 10 were separately incubated with AMACR in 1 1 H NMR spectra showed two overlapping series of peaks corresponding to the 2-H, the 2-Me, the NCHMe and the amide NH (Fig. 2B) , showing that chiral inversion had occurred. The ratio of the two epimeric products in both cases was close to 1 : 1, consistent with observations for 2-methyldecanoyl-CoA 11 (K eq = 1.09 AE 0.14; S/R).
17 Similar treatment of the 2-APAs without exposure to the enzyme gave single sets of signals, confirming that the configuration of the chiral centre was maintained during derivatization ( Fig. 2A) . Exchange of the a-proton is obligatory for chiral inversion and, since no exchange is observed with heat-inactivated enzyme, this demonstrates that chiral inversion is enzyme-catalysed.
Kinetic parameters for the 2-APA-CoA and S-2-methyldecanoyl-CoA esters were then determined ( Table 1 ). All the 2-APA-CoA esters were good substrates of human AMACR 1A. Flurbiprofenoyl-CoA 8, ibuprofenoyl-CoA 2 and naproxenoylCoA 10 were converted about as efficiently as S-2-methyldecanoyl-CoA 11 (as judged by k cat /K m ). The results also suggest that the limited chiral inversion of flurbiprofen 10 in humans is due to low conversion to its CoA ester 8 in vivo rather than it not being a chiral inversion substrate. Ketoprofenoyl-CoA 9 was converted ca. twice as efficiently as S-2-methyldecanoyl-CoA 11. Fenoprofenoyl-CoA 7 was by far the best substrate (k cat /K m = ca. 1400 M À1 s
À1
), largely due to the very low estimated K m value (2.3 mM cf. 26-74 mM for other substrates). Examination of the kinetic plots for 7 showed near-saturation even at the lowest substrate concentrations and it is possible that the K m value is significantly lower than estimated by this assay. It was not possible to use significantly lower substrate concentrations, as a tight binding situation would occur, i.e. the concentrations of substrate and enzyme would be similar. Interestingly, the K m for 7 is of similar magnitude to the K i values for the best inhibitors of the rat enzyme (ca. 0.9 mM).
20
Literature inhibitors of AMACR 20 increase the acidity of the a-proton using electron-withdrawing groups, to facilitate deprotonation and mimic the deprotonated intermediate. The aliphatic side-chain of S-2-methyldecanoyl-CoA 11 is electron-donating and replacement with any aryl side-chain will make the a-proton more acidic. 2-APA-CoA substrates are expected to be more tightly bound based on this argument and lower K m values are observed. Substrates with aromatic rings substituted with electron-withdrawing groups (e.g. 8) are expected to have particularly acidic a-protons and this may explain its tight binding.
There is no reported structure for AMACR, but the structure of the M. tuberculosis homologue with a number of acyl-CoA has been reported. 21 These structures show the CoA moiety locked into the active site by a network of hydrogen bonds and ionic interactions. The carboxylate thioester and methyl groups of the substrate are close to the catalytic residues. The substrate side-chains are directed to the methioninerich surface at the active site entrance. AMACR is expected to bind substrates in broadly similar manner and this explains the diverse structures of known substrates. 16 However, these factors do not explain the low K m value of fenoprofenoyl-CoA 7.
Post facto molecular modelling studies were undertaken to try to rationalize the binding of 2-APA-CoAs to AMACR. 
